The most commonly reported effects are mild injection-site irritation, short-term fatigue during TB-500 loading, and occasional headache
The injection site should always be cleaned with an alcohol swab and allowed to dry before injecting
What FDA has said recently (high-level, patient-friendly summary) FDA maintains a page describing certain bulk drug substances used in compounding that may present significant safety risks, including AOD-9604, noting concerns such as potential immunogenicity and limited safety-related information for some uses/routes
The FDA placed BPC-157 in 503A Category 2 in 2023, which blocked compounding pharmacies from preparing it
The timeline varies based on individual factors including starting point, dosing, diet, and exercise habits
Memberships Specials at IntraVenous Solutions In line with our dedication to affordability, were excited to offer seasonal promotions throughout the year